Does granulocyte transfusion help pediatric cancer patients with sepsis?

Abstract

AbstractSepsis‐related mortality continues to be a major concern while treating pediatric cancer patients, more so with the rise in the incidence of multidrug‐resistant organisms (MDRO). In this retrospective study conducted between January 2021 and December 2022 at a tertiary cancer center in India, granulocyte transfusion was offered in addition to standard antimicrobial therapy to 64 children with hematolymphoid malignancy who developed 75 episodes of severe sepsis following intensive chemotherapy. Forty‐four (83%) of 53 blood culture proven sepsis was caused by MDROs. Thirty‐seven (70%) patients with blood culture proven sepsis cleared the organism after granulocyte transfusion. Thirty‐day mortality was 25% for the entire study cohort and 32% for patients with MDRO sepsis.